Immunic Therapeutics

Immunic Therapeutics Menu
  • Home
  • The Company
    • Management
    • Board of Directors
    • Scientific-Medical Advisory Board
  • Technology
    • Pipeline
    • IMU-838
    • IMU-935
    • IMU-856
    • Scientific Publications
  • News
  • Investor Relations
  • Jobs
  • Contact
Menu
  • IR Home
  • IR Home
  • News Releases
  • Events and Presentations
  • Stock Information
    • Stock Quote
    • Interactive Stock Chart
    • Key Ratios
    • Analyst Coverage
    • FAQs
  • Financials and SEC Filings
    • Annual Reports and Proxies
    • Quarterly Financial Reports
    • SEC Filings
  • Corporate Governance
    • Documents and Charters
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Contact Us

News Releases

Investor Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Sep 8, 2020
    Immunic, Inc. to Participate in Scientific and Investor Conferences in September
  • Aug 20, 2020
    Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
  • Aug 10, 2020
    Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares
  • Aug 4, 2020
    Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock
  • Aug 3, 2020
    Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock
Show 5102550100 per page
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 16
  • »
  • Home
  • Management
  • Board of Directors
  • Scientific-Medical Advisory Board
  • Pipeline
  • IMU-838
  • IMU-935
  • IMU-856
  • Scientific Publications
  • News
  • Investor Relations
  • Jobs
  • Contact
  • Datenschutzerklärung
  • Imprint
This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies
f